Foundation News

Relapsing Polychondritis Foundation Renews Partnership with NYU Grossman School of Medicine to Invest in Next Phase of VEXAS Research

The Relapsing Polychondritis (RP) Foundation is pleased to announce it will continue and expand its partnership with NYU Grossman School of Medicine to invest in and advance the next phase of collaborative VEXAS research.

RP Foundation at Rare Disease Day 2023

We’re excited to share that we represented relapsing polychondritis at the NIH Rare Disease Day. The goal of this event is to raise rare disease awareness, spotlight those impacted by rare diseases, and NIH collaborations that advance research for new treatments.

New Study by Relapsing Polychondritis Foundation Research Partners Shows VEXAS Syndrome May Be More Common Than Many Other Inflammatory Conditions

New York – January 25, 2023 – This information is from the Relapsing Polychondritis Foundation Inc. (RP Foundation) with Race for RP. A new study by investigators from the National Institutes of Health (NIH) and New York University Grossman School of Medicine (NYU Grossman), published online in the Journal of the American Medical Association (JAMA) on January 24, found that the recently discovered inflammatory disease VEXAS syndrome is more common than previously understood.

Relapsing Polychondritis Foundation Announces Appointment of Frances Sweeney to Board of Directors

The Relapsing Polychondritis Foundation (RP Foundation) is pleased to announce the appointment of Frances “Fran” Sweeney to its Board of Directors effective December 11, 2022.

Thank You for an Exceptional 2022

In these final weeks of 2022, as you connect with family and friends to celebrate the holiday seasons, the RP Foundation and Race for RP extend our heartfelt thanks for the partnership and support you generously share with us.

2022: Celebrating A Year Filled with Progress and Discoveries!

In 2022, the Relapsing Polychondritis Foundation, Race for RP, and our incredible partners helped drive RP and related autoimmune diseases to the forefront of ground-breaking scientific discoveries. We also improved patient access to specialized, multi-disciplinary teams of clinicians and fostered a greater understanding of RP among clinicians, scientists, and the broader community.